Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Ophthalmia

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    17 result(s) found for: Ophthalmia. Displaying page 1 of 1.
    EudraCT Number: 2013-004973-29 Sponsor Protocol Number: CL3-78989-019 Start Date*: 2014-08-13
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: A safety open-label study of Gevokizumab in the treatment of patients with chronic non-infectious Uveitis disease, an eXtension study. The EYEGUARD-X study.
    Medical condition: chronic non-infectious uveitis
    Disease: Version SOC Term Classification Code Term Level
    18.0 10015919 - Eye disorders 10022557 Intermediate uveitis LLT
    18.0 10038359 - Renal and urinary disorders 10069034 Tubulointerstitial nephritis and uveitis syndrome PT
    18.0 100000004862 10036370 Posterior uveitis LLT
    18.0 100000004866 10071139 Behcet's uveitis LLT
    18.0 10015919 - Eye disorders 10042745 Sympathetic uveitis LLT
    18.0 10015919 - Eye disorders 10012692 Diabetic uveitis PT
    18.0 10015919 - Eye disorders 10046851 Uveitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended) IT (Completed) PT (Completed) ES (Completed) AT (Completed) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-001610-42 Sponsor Protocol Number: X052130/CL3-78989-005 Start Date*: 2013-01-24
    Sponsor Name:XOMA (US) LLC
    Full Title: A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Non-infectious Intermediate, Posterior, or Pan- Uveitis
    Medical condition: Non-infectious Intermediate, Posterior, or Pan- Uveitis
    Disease: Version SOC Term Classification Code Term Level
    17.0 10015919 - Eye disorders 10022557 Intermediate uveitis PT
    17.0 10038359 - Renal and urinary disorders 10069034 Tubulointerstitial nephritis and uveitis syndrome PT
    17.0 10015919 - Eye disorders 10033687 Panuveitis LLT
    17.0 100000004862 10036370 Posterior uveitis LLT
    17.0 10015919 - Eye disorders 10066681 Acute uveitis LLT
    17.0 100000004866 10071139 Behcet's uveitis LLT
    17.0 10015919 - Eye disorders 10042745 Sympathetic uveitis LLT
    17.0 10015919 - Eye disorders 10012692 Diabetic uveitis PT
    17.0 10015919 - Eye disorders 10046851 Uveitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) PT (Completed) GB (Prematurely Ended) ES (Completed) GR (Prematurely Ended) AT (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-001609-25 Sponsor Protocol Number: X052131/CL3-78989-006 Start Date*: 2013-01-02
    Sponsor Name:XOMA (US) LLC
    Full Title: A RandomizEd, Double-masked, Placebo-controlled Study of the SafetY and Efficacy of GevokizUmAb in the TReatment of Subjects with Non-infectious IntermeDiate, Posterior, or Pan- uveitis Currently C...
    Medical condition: Non-infectious Intermediate, Posterior, or Pan- Uveitis
    Disease: Version SOC Term Classification Code Term Level
    17.0 10015919 - Eye disorders 10022557 Intermediate uveitis PT
    17.0 10038359 - Renal and urinary disorders 10069034 Tubulointerstitial nephritis and uveitis syndrome PT
    17.0 100000004862 10036370 Posterior uveitis LLT
    17.0 100000004866 10071139 Behcet's uveitis LLT
    17.0 10015919 - Eye disorders 10042745 Sympathetic uveitis LLT
    17.0 10015919 - Eye disorders 10012692 Diabetic uveitis PT
    17.0 10015919 - Eye disorders 10046851 Uveitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended) PT (Completed) IT (Completed) GR (Prematurely Ended) ES (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-014054-14 Sponsor Protocol Number: SILC 201109v2 Start Date*: 2010-05-28
    Sponsor Name:Guys' and St Thomas' NHS Foundation Trust, Joint Clinical Trials Office
    Full Title: Comparison of the Safety of Intracameral Levofloxacin to intracameral Cefuroxime for the prevention of endophthalmitis in cataract surgery (SILC)
    Medical condition: Cataracts and endophthalmitis
    Disease: Version SOC Term Classification Code Term Level
    12 10006379 Cataract Surgery PT
    12 10014801 Endophthalmitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-000319-96 Sponsor Protocol Number: NVG 05L101 Start Date*: 2006-06-05
    Sponsor Name:Novagali Pharma SA
    Full Title: “Estudio de fase II/III, Multicéntrico, doble enmascarado, Aleatorizado, de Grupos paralelos, Con variacion de dósis, controlado para valorar la eficacia y seguridad de NOVA22007 (emulsión ocular c...
    Medical condition: Queratoconjuntivitis vernal
    Disease: Version SOC Term Classification Code Term Level
    8.0 10047317 LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2017-002729-39 Sponsor Protocol Number: C-07-40 Start Date*: 2017-11-07
    Sponsor Name:Alcon Research Ltd
    Full Title: An Evaluation of the Safety and Efficacy of Moxifloxacin AF Ophthalmic Solution 0.5% for the Treatment of Bacterial Conjunctivitis in the USA
    Medical condition: Bacterial conjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10061784 Conjunctivitis bacterial PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-002730-23 Sponsor Protocol Number: C-04-38 Start Date*: 2017-11-07
    Sponsor Name:Alcon Research Ltd
    Full Title: An Evaluation of the Safety and Efficacy of Moxifloxacin AF Ophthalmic Solution 0.5% for the Treatment of Bacterial Conjunctivitis in the USA
    Medical condition: Bacterial conjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10061784 Conjunctivitis bacterial PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-002727-24 Sponsor Protocol Number: C-10-051 Start Date*: 2017-11-07
    Sponsor Name:Alcon Research
    Full Title: An Evaluation of the Safety and Efficacy of Moxifloxacin Ophthalmic Solution 0.5% Versus Ofloxacin Ophthalmic Solution 0.3% in the Treatment of Bacterial Conjunctivitis in Chinese Patients
    Medical condition: bacterial conjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10061784 Conjunctivitis bacterial PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2020-005263-31 Sponsor Protocol Number: LEVOKETO_02-2020 Start Date*: 2021-06-02
    Sponsor Name:NTC SRL
    Full Title: Assessment of the effects and tolerability of RD03/2016 (Levofloxacin; Ketorolac Trometamol 0.5+0.5% w/v eye drops solution) for the treatment of bacterial conjunctivitis in adults: a multicentre, ...
    Medical condition: Bacterial conjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10061784 Conjunctivitis bacterial PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) IT (Completed) DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-003361-25 Sponsor Protocol Number: SHP640-303 Start Date*: Information not available in EudraCT
    Sponsor Name:Shire Human Genetic Therapies, Inc.
    Full Title: A Phase 3, Multi-center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of SHP640 (PVP-Iodine 0.6% and Dexamethasone 0.1%) Ophthalmic Suspension Compared to Placebo in...
    Medical condition: Bacterial Conjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10061784 Conjunctivitis bacterial PT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) EE (Completed) HU (Completed) ES (Completed) PL (Completed) AT (Completed) FR (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-006545-13 Sponsor Protocol Number: LX211-03-UV Start Date*: 2007-04-27
    Sponsor Name:Lux Biosciences GmbH
    Full Title: A Double-Masked, Placebo-Controlled, Multi-Centre, Dose-Ranging Study to Assess the Efficacy and Safety of LX211 as Therapy in Subjects with Active Sight Threatening, Non-Infectious Uveitis.
    Medical condition: Subjects with active sight-threatening, non-infectious anterior, anterior and intermediate- or panuveitis who require systemic immunosuppression for the control of their disease.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10046851 Uveitis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) GB (Completed) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-004709-24 Sponsor Protocol Number: CERL080ANL05 Start Date*: 2007-03-20
    Sponsor Name:ErasmusMC
    Full Title: Mycophenolate sodium (Myfortic®) in the Treatment of Uveitis: a Pilot Study.
    Medical condition: Uveitis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10046851 Uveitis LLT
    Population Age: Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-006543-31 Sponsor Protocol Number: LX211-01-UV Start Date*: 2007-04-13
    Sponsor Name:Lux Biosciences GmbH
    Full Title: A Double-Masked, Placebo-Controlled, Parallel-Group, Multi-Center, Dose-Ranging Study with an Optional Extension to Assess the Efficacy and Safety of LX211 as Therapy in Subjects with Active Sight ...
    Medical condition: Subjects with active sight-threatening, non-infectious intermediate-, anterior and intermediate-, posterior- or pan-uveitis.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10046851 Uveitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) GB (Completed) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-004952-80 Sponsor Protocol Number: A0661158 Start Date*: 2015-04-03
    Sponsor Name:Pfizer Inc
    Full Title: Phase 3, Open-Label, Randomized, Comparative Study to Evaluate Azithromycin plus Chloroquine and Sulfadoxine plus Pyrimethamine Combinations for Intermittent Preventive Treatment of Falciparum Mala...
    Medical condition: Intermittent Preventive Treatment In Pregnancy (IPTp)
    Disease: Version SOC Term Classification Code Term Level
    17.1 10021881 - Infections and infestations 10025487 Malaria PT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2006-006544-66 Sponsor Protocol Number: LX211-02-UV Start Date*: 2007-04-13
    Sponsor Name:Lux Biosciences GmbH
    Full Title: A Double-Masked, Placebo-Controlled, Parallel-Group, Multi-Centre, Dose-Ranging Study with an Optional Extension to Assess the Efficacy and Safety of LX211 as Therapy in Subjects with Clinically Qu...
    Medical condition: Subjects with clinically quiescent sight-threatening, non-infectious intermediate-, anterior and intermediate-, posterior- or pan-uveitis requiring systemic immune suppression.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10046851 Uveitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) GB (Completed) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-003567-39 Sponsor Protocol Number: LT1225-PIIIB-02/08 Start Date*: 2008-08-04
    Sponsor Name:Laboratoires Thea
    Full Title: clinical efficacy and safety of azyter (azythromycin 1,5%) versus tobramycin 0,3% eye drops in the treatment of purulent bacterial conjonctivitis of children. multicenter, international, investigat...
    Medical condition: This trial will be performed on children aged from one day of life to 18 years old. The medical conditions that will be observed is the purulent bacterial conjonctivitis.
    Disease:
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed) DE (Completed) ES (Completed) PT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-005060-10 Sponsor Protocol Number: NVG09B113 Start Date*: 2013-04-08
    Sponsor Name:Novagali Pharma S.A.S.
    Full Title: A MULTICENTER, RANDOMIZED, DOUBLE-MASKED, 3 PARALLEL ARMS, PLACEBO CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF NOVA22007 1MG/ML (CICLOSPORIN/CYCLOSPORINE) EYE DROPS, EMULSION ADMINISTERED...
    Medical condition: Vernal Keratoconjunctivitis (VKC)
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004853 10057383 Allergic keratoconjunctivitis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) IT (Completed) DE (Completed) PT (Completed) ES (Completed) GR (Completed) HR (Completed) FR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 20 15:21:51 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA